
Surginex
Innovative biotech solutions leveraging AI and CRISPR-Cas9 for advanced genetic research and therapeutic development.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
* | KRW8.5b | Early VC | |
Total Funding | 000k |
Related Content
Surginex operates in the biotechnology sector, focusing on advanced genetic research and therapeutic development. The company leverages cutting-edge technologies such as Artificial Intelligence (AI) and CRISPR-Cas9 to innovate in the field of genetic engineering. Surginex serves a diverse clientele, including academic institutions, pharmaceutical companies, and research organizations. The business model revolves around providing specialized research services and developing proprietary therapeutic solutions. Revenue is generated through service contracts, licensing agreements, and partnerships with other biotech firms. Surginex's market is highly specialized, targeting sectors that require advanced genetic manipulation and data analysis capabilities. The company is led by a team of experts with extensive experience in AI and genetic research, ensuring a strong foundation for innovation and growth.
Keywords: biotechnology, genetic research, AI, CRISPR-Cas9, therapeutic development, academic institutions, pharmaceutical companies, research services, licensing agreements, proprietary solutions.